Posted by Michael Wonder on 16 Dec 2020
NICE recommends Novartis’ wet AMD drug Beovu
16 December 2020 - The UK’s NICE has recommended Novartis’ anti-VEGF treatment Beovu (brolucizumab) for routine NHS use in wet age-related degeneration patients.
The final appraisal determination recommendation was based on the results from Novartis’ Phase 3 HAWK and HARRIER trials, in which Beovu met the primary outcome.
